We found that Prabotulinumtoxin A (Nabota^®^) injection in patients with cervical and shoulder girdle myofascial pain syndrome significant decreased both pain scale and Neck Disability Index scores. There were no adverse events related to vital signs; physical and neurological examinations; and laboratory tests.

1. Introduction {#sec1-toxins-10-00355}
===============

Myofascial pain syndrome is a chronic pain syndrome caused by myofascial trigger points, most commonly those of the neck and shoulder. Treatments for myofascial pain syndrome include pharmacotherapy, physical therapy, therapeutic exercise, and trigger point injections \[[@B1-toxins-10-00355]\].

Trigger point injections are treatments that directly target myofascial trigger points using local anesthetics. They are typically performed several times per week. However, botulinum toxin can be administered in a single injection that lasts for many months \[[@B2-toxins-10-00355],[@B3-toxins-10-00355],[@B4-toxins-10-00355]\].

Zhou et al. \[[@B5-toxins-10-00355]\] described the potential effects of botulinum toxin in myofascial pain syndrome, and Nicol et al. \[[@B4-toxins-10-00355]\] reported that botulinum toxin improved pain and quality of life in patients with cervical and shoulder girdle myofascial pain syndrome.

Nabota^®^ is a botulinum toxin type A protein of high purity and quality developed by Daewoong Pharmaceutical in Korea, from the natural strain Clostridium botulinum (type A). Clinical trials have been conducted to demonstrate its effects on skin wrinkles and upper limb spasticity in stroke patients \[[@B6-toxins-10-00355],[@B7-toxins-10-00355]\].

The purpose of the present study was to confirm the efficacy and safety of Prabotulinumtoxin A (Nabota^®^) injection in patients with cervical and shoulder girdle myofascial pain syndrome.

2. Results {#sec2-toxins-10-00355}
==========

In total, 12 patients with cervical and shoulder girdle myofascial pain syndrome were enrolled in this study. The demographic information and pain rating scales are presented in [Table 1](#toxins-10-00355-t001){ref-type="table"}. The baseline characteristics of the patients according to the clinical variables are presented in [Table 2](#toxins-10-00355-t002){ref-type="table"}.

There was a statistically significant difference in pain scores after 12 weeks compared to baseline (*p* \< 0.0001). However, there was no statistically significant difference either post-injection (*p* = 0.88) or after 6 weeks compared (*p* = 0.06) to baseline. The pain rating scale values were 5.1 ± 0.3, 4.8 ± 0.4, 4.2 ± 1.2 and 2.6 ± 1.3 at baseline, post-injection, 6 weeks, and 12 weeks, respectively ([Figure 1](#toxins-10-00355-f001){ref-type="fig"}). The proportion of patients whose pain scores improved by 30% or more was 8.33% at post-injection, 41.7% at 6 weeks, and 75% at 12 weeks.

There was a statistically significant improvement in disability using the Neck Disability Index after 6 weeks (*p* = 0.01) and 12 weeks (*p* = 0.001) compared to baseline. However, there was no statistically significant difference post-injection (*p* = 0.37) compared to baseline. The Neck Disability Index values were 32.1 ± 11.9, 33.3 ± 32.3, 23.4 ± 14.7, and 17.8 ± 13.6 at baseline, post-injection, 6 weeks, and 12 weeks, respectively ([Figure 2](#toxins-10-00355-f002){ref-type="fig"}).

The average dose given to patients was 171.9 ± 25.1 units. A safety evaluation, including adverse events and adverse drug reactions, laboratory tests, vital signs, and physical and neurological examinations, was conducted for all patients who received the drug in this clinical trial. There were no adverse events reported regarding changes in vital signs and physical examination findings.

3. Discussion {#sec3-toxins-10-00355}
=============

This study evaluated the efficacy and safety of Prabotulinumtoxin A (Nabota^®^) in patients with cervical and shoulder girdle myofascial pain syndrome. A previous study \[[@B4-toxins-10-00355]\] showed that botulinum toxin A injection improved pain scores and quality of life in patients with myofascial pain syndrome. We found that Nabota^®^ injection in patients with cervical and shoulder girdle myofascial pain syndrome significant decreased both pain scale and Neck Disability Index scores. There were no adverse events related to vital signs, physical and neurological examinations, and laboratory tests.

Our study results are similar to previous studies \[[@B2-toxins-10-00355],[@B3-toxins-10-00355],[@B4-toxins-10-00355]\] of Botulinum toxin A injection for myofascial pain syndrome in relation to improvements in chronic pain. The pain rating score was significantly decreased from 5.1 to 2.6 at 12 weeks after the Nabota^®^ injection. A previous systemic review \[[@B8-toxins-10-00355]\] documented that pain was reduced by Botulinum toxin A at 2 to 6 months after injection but not at 4 to 6 weeks. Our results showed that, in 75% of patients, the pain score had significantly improved at 12 weeks, and 41.7% of the patients had decreased pain scores at 6 weeks.

In a study by Nicol et al. \[[@B4-toxins-10-00355]\], 50% of patients responded to injections of Botulinum toxin A in the first phase of the study. In our study, 41.7% of patients' pain scores improved by at least 30% at 6 weeks. This shows that the efficacy of Nabota^®^ in myofascial pain syndrome is similar to that of Botulinum toxin A injection.

The results of the present study are consistent with those of earlier studies \[[@B3-toxins-10-00355],[@B4-toxins-10-00355]\] that reported significant improvements in quality of life in patients with myofascial pain syndrome. We also found that Neck Disability Index scores, which were used to compare the degree of neck/shoulder function improvement, were statistically significantly improved after 6 and 12 weeks. The mean score was 32.1 before drug administration, 23.4 at 6 weeks after Nabota^®^ treatment, and 17.8 after 12 weeks.

Possible adverse effects related to botulinum toxin injection for myofascial pain syndrome include regional weakness, limb numbness, limb coldness, sore throat, nausea, flu-like symptoms, sore muscles, decreased systolic blood pressure, and arthralgia \[[@B2-toxins-10-00355],[@B3-toxins-10-00355],[@B4-toxins-10-00355],[@B9-toxins-10-00355]\]. A previous study \[[@B7-toxins-10-00355]\] reported adverse events of Nabota^®^ related to the musculoskeletal system, such as muscular weakness, muscle atrophy, and pain in the extremities. In the present study, there were no adverse reactions documented from the laboratory tests, vital signs, and physical and neurological examinations.

Prabotulinumtoxin A (Nabota^®^), a new botulinum toxin A originating from wild-type Clostridium botulinum A, presents higher purity of botulinum toxin A, which is confirmed by size exclusion high-performance liquid chromatography analysis \[[@B7-toxins-10-00355]\]. This trial is the first study for safety and efficacy of Prabotulinumtoxin A (Nabota^®^) injection into painful muscle groups for myofascial pain.

The trigger point is defined as a palpable and hyperirritable nodule located in a taut band of muscle. Botulinum toxin A is effective in focal muscle hyperactivity \[[@B10-toxins-10-00355]\]. In fact, electromyography activity at the trigger point demonstrates focal muscle hyperactive that play a significant role in the pain mechanisms \[[@B11-toxins-10-00355]\]. Botulinum toxin A provides long lasting pain relief by causing prolonged muscle relaxation through inhibition of acetylcholine release. Botulinum toxin also inhibits the release of inflammatory mediators and peripheral neurotransmitters from sensory nerves \[[@B12-toxins-10-00355]\]. These compounds are thought to be involved in peripheral and central sensitization in chronic myofascial pain. In the present study, the mean pain duration of the subjects was 20.3 months. Patients with chronic myofascial pain were effectively treated by botulinum toxin injection.

4. Study Limitations {#sec4-toxins-10-00355}
====================

The main limitation of this study was the relatively small number of patients. Although other preliminary studies have used fewer subjects and no controls, it is difficult to reach definite conclusions using this data set.

5. Conclusions {#sec5-toxins-10-00355}
==============

In conclusion, Nabota^®^ injection improved pain and quality of life after 12 weeks in patients with chronic cervical and shoulder girdle myofascial pain syndrome. This study confirmed that Nabota^®^ injection was a safe procedure for all of the patients. As this study is a preliminary study, we expect that further inquiries should carefully consider using randomized, controlled, prospective trials.

6. Material and Methods {#sec6-toxins-10-00355}
=======================

Subjects
--------

This study was conducted with the approval by the Catholic University of Korea, Incheon St. Mary's Hospital Institutional Research Review Board (IRB No. OC14MISI0102). This clinical trial was registered with the Clinical Research Information Service (CRIS, <https://cris.nih.go.kr/cris/en/>) under number (KCT0001634), approved on 23 September 2015. Twelve patients were enrolled in this prospective study, all of whom agreed in writing to voluntarily participate in the clinical trial and met the screening criteria. The inclusion criteria were as follows: (1) Male or female subjects no younger than 20 years; (2) myofascial pain of the neck and shoulders of at least 3-months duration; (3) failed standard therapy (i.e., physical modality, exercise, medication, and trigger point injections other than botulinum toxin A); (4) pain scale score of 5 or higher, and (5) voluntary informed consent signed by the patient after the objectives and methods of the clinical study had been explained. The exclusion criteria were as follows: (1) Patients with a history of neuromuscular disease; (2) patients receiving botulinum toxin A therapy within the past 4 months; (3) patients with a known allergy or sensitivity to any component of the test medication; (4) subjects who were pregnant or breastfeeding; (5) patients with significant atrophy of the muscles in the target injection area; (6) patients with muscle weakness in the target area (i.e., a Medical Research Council score \< 5); (7) subjects deemed inappropriate for entry into this study in the judgement of the investigator; (8) patients taking muscle-relaxant drugs within 4 weeks prior to the screening visit; (9) patients taking aspirin, nonsteroidal anti-inflammatory drugs or antiplatelet drugs; (10) patients with another active illness; (11) patients with a moderate degree of cardiac disease or pulmonary disease; (12) patients with a herniated cervical nucleus pulposus, a straight cervical spine or a cervical sprain, and (13) patients who had participated in an investigational drug study or bioequivalence study within 3 months prior to the screening visit.

For the injections, one vial of Nabota^®^ (100 Units) was diluted with 4 mL of saline. The painful muscle containing the trigger point was injected with up to 50 Units of Nabota^®,^ and a maximum of 200 Units was allowed for each patient. The target muscle and dose for each injection were selected by a single skilled physician. The injection sites and doses for each muscle are shown in [Table 3](#toxins-10-00355-t003){ref-type="table"}.

All patients received follow-up visits at 6 and 12 weeks after the injection. At each visit, the safety and efficacy of the drug were evaluated through a physical examination as well as a numerical rating scale for pain and a Neck Disability Index. The primary outcome measure was the percentage of patients whose pain scores (numerical rating scale) improved by 30% or more at 6 and 12 weeks after the injection compared to baseline. Disability as a secondary outcome was quantified using the Neck Disability Index.

Statistical analyses were performed using SAS^®^ software, version 9.3 (Cary, NC, USA). Paired *T*-test or Wilcoxon signed-rank test were used to evaluate differences in the pain scale and Neck Disability Index. A *p*-value \< 0.05 was considered statistically significant.

Data management and statistical analysis were performed by Daewoong Pharmaceutical Financial.
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toxins-10-00355-t001_Table 1

###### 

Patient demographic information and pain rating scales.

  Patient   Age (years)   Gender   Height (cm)   Weight (kg)   Duration of Pain (Months)   Pain Rating Scale           
  --------- ------------- -------- ------------- ------------- --------------------------- ------------------- --- --- ---
  1         26            Female   158           41            10                          5                   5   5   5
  2         42            Female   165           63            10                          5                   4   3   1
  3         33            Female   170           68            24                          5                   5   3   2
  4         36            Female   161           56            60                          5                   5   5   2
  5         35            Female   160           56            10                          6                   5   4   3
  6         39            Female   167           61            24                          5                   5   5   3
  7         58            Female   154           51            24                          5                   5   5   4
  8         44            Female   159           58            30                          5                   8   2   1
  9         36            Female   162           53            12                          5                   5   5   3
  10        22            Female   163           63            12                          5                   5   5   2
  11        23            Female   162           58            12                          5                   5   2   1
  12        24            Female   160           57            15                          5                   3   5   4

toxins-10-00355-t002_Table 2

###### 

Baseline characteristics of the patients.

  Variable                    Value (Mean ± Standard Deviation)
  --------------------------- -----------------------------------
  Age                         34.8 ± 10.4
  Female Gender               12 ^a^
  Height (cm)                 161.8 ± 4.2
  Weight (Kg)                 57.1 ± 6.9
  Duration of Pain (Months)   20.3 ± 14.3

^a^ presented as number; The mean age was 34.8 ± 10.4 years, all of the patients were female, and none had previous injections of botulinum toxin.

toxins-10-00355-t003_Table 3

###### 

Injection sites and dose for each muscle.

  Patient   Anterior Musculature (Units)   Posterior Musculature (Units)                                           
  --------- ------------------------------ ------------------------------- ------ ------ ------ ------ ---- ------ ------
  1         6.25                           6.25                                                 6.25   25   125    6.25
  2         6.25                           6.25                                   6.25          25     25   6.25   6.25
  3         6.25                           6.25                                                 25     25   6.25   6.25
  4         6.25                           6.25                            12.5                 25     25   6.25   6.25
  5         6.25                           6.25                                   6.25   6.25   25     25   6.25   6.25
  6         6.25                           6.25                                                 25     25   6.25   6.25
  7         6.25                           6.25                            12.5                 25     25   6.25   6.25
  8         6.25                           6.25                            12.5          12.5   25     25   6.25   6.25
  9                                                                                      12.5   25     50   6.25   6.25
  10        6.25                           6.25                                                 25     50   6.25   6.25
  11        6.25                           6.25                                                 25     50   6.25   6.25
  12        6.25                           6.25                                                 25     25   6.25   6.25
